Clinical trial
A Randomized, Double Blind, Active Control, Flexible Dose, Multicenter Study to Evaluate Galantamine HBr in the Treatment of Alzheimer's Disease:Safety and Effectiveness of an Immediate-release Table Formulation.
NCT00645190 is registered in ClinicalTrials.gov with Xian-Janssen Pharmaceutical Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double Blind, Active Control, Flexible Dose, Multicenter Study to Evaluate Galantamine HBr in the Treatment of Alzheimer's Disease:Safety and Effectiveness of an Immediate-release Table Formulation.
- Lead sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2004
- Completion date
- February 28, 2005
- Enrollment
- 215 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.